Expand AEON Menu
AEON MENU

AEON Latest Press Releases

-- September 30, 2026 --

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 Globe Newswire 8:00 AM

-- September 9, 2026 --

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX Globe Newswire 8:00 AM

-- August 31, 2026 --

AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference Globe Newswire 8:00 AM

-- August 24, 2026 --

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer Globe Newswire 8:00 AM

-- August 19, 2026 --

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX Globe Newswire 8:00 AM

-- August 12, 2026 --

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:15 PM

-- August 3, 2026 --

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards Globe Newswire 4:15 PM

-- July 14, 2026 --

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding Globe Newswire 8:00 AM

-- June 4, 2026 --

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society Globe Newswire 7:00 AM

-- May 14, 2026 --

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes